optic neuritis current diagnosis and management
play

Optic Neuritis: Current Diagnosis and Management Age 20 to 50 - PowerPoint PPT Presentation

2/12/2014 Acute Optic Neuritis: Typical History Optic Neuritis: Current Diagnosis and Management Age 20 to 50 years Unilateral Visual loss does not progress beyond 14 days Pain is present, particularly on eye movements


  1. 2/12/2014 Acute Optic Neuritis: Typical History Optic Neuritis: Current Diagnosis and Management • Age 20 to 50 years • Unilateral • Visual loss does not progress beyond 14 days • Pain is present, particularly on eye movements • Visual recovery begins by one month Acute Optic Neuritis: Optic Disc Appearance Typical Findings • Reduced acuity in one eye • Vision better than no light perception • Impaired color vision • Afferent pupil defect • Field loss- diffuse, central, arcuate, altitudinal • Mild or no disc swelling • No hemorrhages or retinal exudates 1

  2. 2/12/2014 Optic Neuritis-Clinical Course • 95% recover to 20/40 or better over several weeks • 50% have some permanent vision loss (contrast sensitivity, color vision, or visual field), particularly with baseline acuity of 20/50 or less Optic Neuritis: Treatment • Current treatment is IV steroids • Vision recovers faster (stops inflammation) • BUT, final vision no better than without steroids • Reduces short term risk of developing MS • No known treatment prevents permanent vision loss, unmet therapeutic need • Most high risk patients are placed on immunomodulatory therapy 2

  3. 2/12/2014 Differential Diagnosis (Step 2) Optic Neuritis: Risk of Multiple Sclerosis • Ischemic optic neuropathy (MS) With Normal MRI • Systemic disease • Neuro-retinitis • No pain 0% • Hereditary disorders • Severe disk edema 0% • Disc hemorrhage 0% • NMO • Macular exudate 0% • NLP vision 0% Arch Neurol , 2008. NLP = no light perception Ischemic Optic Neuropathy NEURITIS VS ISCHEMIA NEURITIS ISCHEMIA Age 30’s 60’s Pain 90% 10% Field central altitudinal Fundus retrobulbar – 2/3 swollen 3

  4. 2/12/2014 DIFFERENTIAL DIAGNOSIS (Step 2) INFLAMMATORY (Bilateral, vitreous cells, hemorrhages ) Syphilis Sarcoid Lyme Viral Neuroretinitis DIFFERENTIAL DIAGNOSIS(Step 2) HEREDITARY - Nutritional (Bilateral central-cecal scotomas) Leber’s B 1 , B 12 Toxic 4

  5. 2/12/2014 Optic Discs, VF and OCT NMO Prognosis: (5 to 10 yrs) Reasons to Distinguish It • 62% have legal blindness in one eye • 50% will need an assistive device Neurology 53:1107,1999 NMO: The Chances NMO Tidbits • Average RNFL thickness ♦ Bilateral- 50% present of NMO present NMO- 63 microns, typical- 88 microns with ON, 20% are bilateral vs 0.4% in Controls- 102 microns ON with MS • About 5% of optic neuritis patients are ♦ Severe acuity loss- < 20/200, about NMO positive 33% • Chronic relapsing idiopathic optic ♦ Recurrent ON- about 20% neuropathy (CRION). Tend to have progression between episodes JNO: 32:154;2012 Neurology 73:302, 2009 5

  6. 2/12/2014 Copper Deficiency Optic Neuropathy Step 3- Tests ♦ MRI head with gad (typical or atypical ON) ♦ LP: IgG index, OCB, cells, protein (atypical ON) ♦ NMO IgG (recurrent, bilateral or severe ON) ♦ Leber’s mutations (severe or bilateral ON) ♦ Serological studies-Atypical ON or systemic symptoms-ESR, ANA, ACE, RPR, Lyme, SSA, SSB, ANCA ♦ Retinal Tests-ERG, Fluorescein angiogram, CAR antibodies, OCT ♦ VER: Subclinical ON, can use low contrast Vision and ON as Ideal Models Comparison of Vision Tests • Axonal and neuronal * (1.9, 3.1) MS Patients: n=130 P <0.001 Disease Free Controls: n=90 loss common 2.5 • Odds ratio in Sensitive visual (1.5, 2.2) favor of MS 2.0 P <0.001 function tests (1.3, 1.9) vs. control (1.2, 1.8) P <0.001 P <0.001 status • (95% CI) for Structure-function 1.5 worse vision correlation can be scores RNFL = ganglion cell axons captured by OCT (non-myelinated) 1.0 High Contrast Low Contrast Contrast Color Vision Acuity ~100% Acuity 1.25% Sensitivity Pelli- D15-DS • Unique opportunity Robson to investigate non- * Low contrast acuity charts best distinguish MS patients vs. controls, accounting for age myelinated axons Balcer LJ, Baier ML, Cohen JA, et al. Neurology 2003;61:1367-1373. 6

  7. 2/12/2014 Worsening Vision by EDSS Progression Status Defining Visual Change • 2 lines (10 letters) = clinically meaningful change? Rosser et al. Invest Ophthalmol Vis Sci 2003. Balcer, et al. Neurology 2007. • 5-letter change more sensitive for high-contrast visual acuity Beck et al. Ophthalmology 2007. • Change by ≥ 7 letters is beyond test- retest variability for low-contrast acuity, correlates w/ QOL Balcer, Pelak et al. Mult Scler 2000. Galetta et al. Ectrims, 2010 Retinal Nerve Fiber Layer Importance of OCT in Optic Neuritis Imaging by Optical Coherence Tomography (OCT) • Allows structure-function correlations • Significant RNFL loss, acute, 99% by 6 months • Optic neuritis as a model RNFL for testing new therapies Petzold A et al. Lancet Neurology 2010. Henderson et al. Brain, 2010 Figure from Frohman, et al. Nat Clin Pract Neurol 2008;4:664-675. 7

  8. 2/12/2014 Quantifying Axonal Loss After OCT in Optic Neuritis Optic Neuritis with OCT • Patients (n=54) with ON, 74% had 20% RNFL loss • Thickness at ≥ 3 months = 78 ± 30 µm in affected eyes • Patients with acute ON (n=54) • RNFL <75 µm vs. ≥ 75 µm predicted visual outcome • Followed for a mean of 13 months • 74% developed significant RNFL thinning 40 50 60 70 80 90 100 110 (20%) in the affected eye 5 Visual Field Mean 0 -5 Deviation (dB) -10 • RNFL values significantly thinner in -15 -20 affected eyes (78 µm) vs. fellow eyes (100 -25 µm, P < 0.0001) -30 -35 Costello F et al. Ann Neurol 2006. Costello F et al. Ann Neurol 2006 Longitudinal Data: RNFL Thinning Relation to Low-Contrast Acuity, for All MS Eyes (n=593) Optic Neuritis History 0 RNFL change from baseline (microns) * Degree of RNFL thinning MS Eyes: n=180 MS ON eyes MS non-ON eyes Disease-free control eyes R N F L th ic k n e s s (m ic r o n s ) significantly greater compared to Disease Free Control Eyes: n=72 0 – 1-year interval 170 -2 n=201 150 P < 0.001 for ON vs. non ON eyes, P = 0.03 for MS non ON vs. controls 130 n=242, p=0.06 110 -4 90 n=109, p<0.001 * 70 -6 50 Overall Temporal Superior Nasal Inferior n=41, p<0.001 * average -8 2 lines low-contrast letter acuity = 7.6 µm RNFL, P < 0.001 0.5 - 1 year >1 - 2 years >2 - 3 years >3 years Follow-up interval, all MS eyes Fisher J et al. Ophthalmology 2006. Talman et al., Ann Neurol 2010. 8

  9. 2/12/2014 Retinal Neuronal Atrophy in MS Eyes Low-Contrast Acuity Reflects Axonal Loss Over Time Ganglion cell dropout Inner nuclear layer RNFL thinning from baseline (microns) Neuron dropout No visual loss Loss of 7 or more letters All MS eyes 0 79% of MS patient eyeballs (N=80) had -2 n = 493 GCL dropout and 40% n = 560 had INL (amacrine and bipolar cell) atrophy -4 -6 n = 67, p<0.001 vs. no visual loss Low-contrast letter acuity, 2.5% Green A et al. Brain 2010. Talman L et al. Ann Neurol 2010. MS vs. Controls Spectral-Domain OCT Ganglion Cell Layer RNFL • High resolution Thickness in microns (4-6 µ m) • Segmentation of retinal layers Above courtesy of James Fujimoto, Ph.D. Tan O, …Schuman JS..., et al. Ophthalmology 2009. P values are from GEE models accounting for age and inter-eye correlations 9

  10. 2/12/2014 Implications 100 • Subclinical injury is common in MS 80 r = 0.31, P=0.0006 • OCT and LCA are important outcome 60 measures for clinical trials in MS 40 r = 0.49, P<0.0001 • In practice, used to detect subtle atrophy, 20 longitudinal changes and macular 0 changes 60 70 80 90 100 Thickness of GCL+IPL (microns) • Correlates with QOL and MRI measures NEI-VFQ-25 Composite (best QOL = 100 points) Low-Contrast 2.5% (number of letters identified correctly) 95% Confidence Interval on Fitted Line • Unmet therapeutic need for neuroprotective therapy in MS 24 Y.O. WOMAN EXAMINATION Acuity: NLP O.D ♦ Decreased vision over 7 days 20/20 O.S. ♦ No pain upon eye movement Pupil: Right amaurotic Motility: Full 10

  11. 2/12/2014 EXAMINATION -MW ♦ Slit lamp exam showed 1+ vitreous cells OD ♦ Tension applanations were 16 OU ♦ Fundus exam revealed the following: LABORATORY ♦ nl lytes, CBC, LFTs ♦ RPR (-), ESR 40, PPD (-), anergy (+) ♦ ANA 1:320, nl complements ♦ (-) anti- dsDNA, -smith, -RNA, -Ro, -La ♦ ACE 53.18 (10-50) ♦ LP:2W 0R protein:29 glucose:59 ♦ nl CXR 11

  12. 2/12/2014 COURSE -MW ♦ Conjunctival and lacrimal biopsies showed non-specific chronic inflammation without granulomas ♦ Gallium scan was normal ♦ She was started on steroids and had no improvement ♦ She underwent biopsy of right optic nerve 12

  13. 2/12/2014 OPTIC NERVE IN SARCOID ♦ Occurs in 1-5% of pts with systemic disease ♦ Five categories – Primary granuloma of the optic nerve – Papillitis – Retrobulbar optic neuritis – Papilledema secondary to increased ICP – Optic atrophy 20 Y.O. MAN ♦ Decreased vision O.U. ♦ Visual acuity 20/200 O.U. ♦ Fields: centrocecal scotomas 13

  14. 2/12/2014 30 Y.O. MAN ♦ Sudden visual loss O.D. ♦ No pain on eye movement Central Serous Chorio- retinopathy OS - OD 14

  15. 2/12/2014 72 Y.O. WOMAN EXAMINATION (August 1996) (August 1996) ♦ Progressive visual loss right eye ♦ Acuities: 20/100+ OD, 20/50+ OS ♦ Right periorbital ache ♦ Pupils: sluggish, no APD ♦ No neurologic or constitutional symptoms ♦ Color: no control OU 15

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend